Werner C Albrich

InstitutionDivision of Infectious Diseases and Hospital Epidemiology
AddressSwitzerland
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 8 Covid-19 publications, with a maximum of 2 publications in January 2021
    All Publications
    Bar chart showing 60 publications over 17 distinct years, with a maximum of 6 publications in 2011 and 2017
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hasan Ali O, Bomze D, Risch L, Brugger SD, Paprotny M, Weber M, Thiel S, Kern L, Albrich WC, Kohler P, Kahlert CR, Vernazza P, Bühler PK, Schüpbach RA, Gómez-Mejia A, Popa AM, Bergthaler A, Penninger JM, Flatz L. Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. Clin Infect Dis. 2021 11 02; 73(9):e2869-e2874. PMID: 32997739.
      Citations: 22     Fields:    Translation:Humans
    2. Kahlert CR, Persi R, Güsewell S, Egger T, Leal-Neto OB, Sumer J, Flury D, Brucher A, Lemmenmeier E, Möller JC, Rieder P, Stocker R, Vuichard-Gysin D, Wiggli B, Albrich WC, Babouee Flury B, Besold U, Fehr J, Kuster SP, McGeer A, Risch L, Schlegel M, Friedl A, Vernazza P, Kohler P. Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers - A multicentre cross-sectional study. Clin Microbiol Infect. 2021 Sep; 27(9):1336-1344. PMID: 34020033.
      Citations: 6     Fields:    Translation:Humans
    3. Sieber P, Flury D, Güsewell S, Albrich WC, Boggian K, Gardiol C, Schlegel M, Sieber R, Vernazza P, Kohler P. Characteristics of patients with Coronavirus Disease 2019 (COVID-19) and seasonal influenza at time of hospital admission: a single center comparative study. BMC Infect Dis. 2021 Mar 17; 21(1):271. PMID: 33731019.
      Citations: 3     Fields:    Translation:Humans
    4. Urwyler P, Charitos P, Moser S, Heijnen IAFM, Trendelenburg M, Thoma R, Sumer J, Camacho-Ortiz A, Bacci MR, Huber LC, Stüssi-Helbling M, Albrich WC, Sendi P, Osthoff M. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19). Trials. 2021 Jan 04; 22(1):1. PMID: 33397449.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    5. Meyer Sauteur PM, Kleger GR, Albrich WC. Acute respiratory distress syndrome during the COVID-19 pandemic: not only SARS-CoV-2. New Microbes New Infect. 2021 Mar; 40:100836. PMID: 33425361.
      Citations: 1     
    6. Signer J, Jonsdottir HR, Albrich WC, Strasser M, Züst R, Ryter S, Ackermann-Gäumann R, Lenz N, Siegrist D, Suter A, Schoop R, Engler OB. Author Correction: In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2. Virol J. 2020 Nov 09; 17(1):172. PMID: 33168000.
      Citations: 2     Fields:    
    7. Kohler PP, Kahlert CR, Sumer J, Flury D, Güsewell S, Leal-Neto OB, Notter J, Albrich WC, Babouee Flury B, McGeer A, Kuster S, Risch L, Schlegel M, Vernazza P. Prevalence of SARS-CoV-2 antibodies among Swiss hospital workers: Results of a prospective cohort study. Infect Control Hosp Epidemiol. 2021 05; 42(5):604-608. PMID: 33028454.
      Citations: 7     Fields:    Translation:Humans
    8. Signer J, Jonsdottir HR, Albrich WC, Strasser M, Züst R, Ryter S, Ackermann-Gäumann R, Lenz N, Siegrist D, Suter A, Schoop R, Engler OB. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2. Virol J. 2020 09 09; 17(1):136. PMID: 32907596.
      Citations: 15     Fields:    Translation:HumansAnimalsCellsPHPublic Health